According to the agreement, HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis, and screening system, to discover novel lead compounds.
The collaboration will use HitGen's libraries containing more than 300bn individually DNA-encoded compounds. The DNA encoding of molecules enables screening and analysis of vast chemical space, supporting MTPC's aim to increase success rates for the generation of target leads for new drugs and to drastically shorten screening timelines for expanding MTPC's pipeline.
Under the terms of the agreement, HitGen will receive technology access and research support payments, and be eligible for milestone payments from MTPC. Financial details were not disclosed.
HitGen has headquarters and custom-built research facilities based in Chengdu, China, with a subsidiary in USA.
HitGen has established an industry-leading platform for early-stage drug discovery research centred on DNA encoded chemical libraries. HitGen's DELs include encoded syntheses for more than 300 bn novel, diverse, drug-like small molecule and macrocycle compounds.
These compounds are members of DELs synthesised from many hundreds of distinct chemical scaffolds, designed and assembled with tractable chemistry based on proven results for identifying drug-like leads against biological targets from known and novel classes.
HitGen is working with multiple pharmaceutical and biotech companies, foundations and research institutes to discover and develop the novel therapeutics of the future.
Mitsubishi Tanabe Pharma Corp., which was founded in 1678, has its headquarters in Doshomachi, Osaka, which is the birthplace of Japan's Pharmaceutical Industry.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval